Darwin Global Management, Ltd. - Q1 2022 holdings

$110 Million is the total value of Darwin Global Management, Ltd.'s 1 reported holdings in Q1 2022. The portfolio turnover from Q4 2021 to Q1 2022 was 92.3% .

 Value Shares↓ Weighting
AZN BuyASTRAZENECA PLCsponsored adr$110,236,000
+269.7%
1,661,684
+224.6%
100.00%
+2095.4%
VERV ExitVERVE THERAPEUTICS INC$0-23,104
-100.0%
-0.13%
ACRS ExitACLARIS THERAPEUTICS INC$0-216,143
-100.0%
-0.48%
FULC ExitFULCRUM THERAPEUTICS INC$0-317,428
-100.0%
-0.86%
CCXI ExitCHEMOCENTRYX INC$0-161,802
-100.0%
-0.90%
VIR ExitVIR BIOTECHNOLOGY INC$0-145,841
-100.0%
-0.93%
KROS ExitKEROS THERAPEUTICS INC$0-111,500
-100.0%
-1.00%
FATE ExitFATE THERAPEUTICS INC$0-153,537
-100.0%
-1.37%
ENTA ExitENANTA PHARMACEUTICALS INC$0-166,190
-100.0%
-1.90%
BNTX ExitBIONTECH SEsponsored ads$0-90,057
-100.0%
-3.55%
INBX ExitINHIBRX INC$0-591,975
-100.0%
-3.95%
NTLA ExitINTELLIA THERAPEUTICS INC$0-605,587
-100.0%
-10.94%
PFE ExitPFIZER INC$0-7,697,762
-100.0%
-69.44%
Original filings

The following EDGAR filing(s) were analyzed to create this report:

  • View 13F-HR filed 2022-05-16
Signatures

The EDGAR filing(s) were signed by:

Top long-term holdings
NameQuarters ownedLatest quarter ownedMax weighting
FATE THERAPEUTICS INC5Q4 202124.2%
KEROS THERAPEUTICS INC5Q1 202312.8%
INHIBRX INC5Q4 20213.9%
ACCELERON PHARMA INC4Q3 202163.4%
AMBRX BIOPHARMA INC4Q3 202367.5%
ARGENX SE4Q3 202370.2%
BRIDGEBIO PHARMA INC4Q3 202125.2%
FULCRUM THERAPEUTICS INC4Q4 20210.9%
ASTRAZENECA PLC3Q2 2022100.0%
INTELLIA THERAPEUTICS INC3Q4 202148.6%

View Darwin Global Management, Ltd.'s complete holdings history.

Latest filings
TypeFiled
13F-HR2024-02-14
SC 13G/A2024-02-14
13F-HR2023-11-14
13F-HR2023-08-14
42023-06-28
SC 13D/A2023-06-28
SC 13D/A2023-05-25
13F-HR2023-05-15
SC 13G2023-04-03
32023-03-08

View Darwin Global Management, Ltd.'s complete filings history.

Compare quarters

Export Darwin Global Management, Ltd.'s holdings